News Image

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Provided By PR Newswire

Last update: Sep 19, 2024

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies

Read more at prnewswire.com

AETHLON MEDICAL INC

NASDAQ:AEMD (2/21/2025, 8:00:08 PM)

After market: 0.6199 +0.04 (+6.26%)

0.5834

-0.03 (-4.25%)



Find more stocks in the Stock Screener

Follow ChartMill for more